RxDoctor Payments Data

Henry Wojtczak

Pediatric Pulmonology · Albuquerque, NMNPI 1346213691

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $144,997 of the $182,809 with a category attached, or 79.3%. 9 manufacturers reported payments, led by Sanofi Pasteur Inc. at 31.0% of the total.

$182,809in general payments, 2019–2025

Across 244 payments — averaging $749.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi Pasteur Inc.$57K
  • Phadia US Inc.$45K
  • Sobi, Inc$44K
  • Gilead$22K
  • Chiesi USA, Inc.$14K
  • Astrazeneca UK Limited$930
  • plus $521 from 3 others
$2,579in research payments, 2019–2025

Across 3 payments — averaging $859.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Chiesi USA, Inc.$3K

What the payments were for

  • Consulting fees$5,5513%
  • Speaking & faculty fees$144,99779%
  • Travel & lodging$24,46913%
  • Food & beverage$7,7934%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few pediatric pulmonology providers in New Mexicoto place this figure against a meaningful peer group, so we don't.

Other pediatric pulmonology in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →